Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Complement and biocompatibility

T E Mollnes1

  • 1Department of Immunology and Transfusion Medicine, Nordland Central Hospital, Bodø, Norway. tomeirik@fagmed.uit.no

Vox Sanguinis
|August 15, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retraction Note: Rifaximin alters gut microbiota profile, but does not affect systemic inflammation - a randomized controlled trial in common variable immunodeficiency.

Scientific reports·2024
Same author

Intracellular Complement Component 3 Attenuated Ischemia-Reperfusion Injury in the Isolated Buffer-Perfused Mouse Heart and Is Associated With Improved Metabolic Homeostasis.

Frontiers in immunology·2022
Same author

Phagocytosis of live and dead Escherichia coli and Staphylococcus aureus in human whole blood is markedly reduced by combined inhibition of C5aR1 and CD14.

Molecular immunology·2019
Same author

Rifaximin alters gut microbiota profile, but does not affect systemic inflammation - a randomized controlled trial in common variable immunodeficiency.

Scientific reports·2019
Same author

Complement component 5 does not interfere with physiological hemostasis but is essential for Escherichia coli-induced coagulation accompanied by Toll-like receptor 4.

Clinical and experimental immunology·2018
Same author

Staphylococcus aureus-induced complement activation promotes tissue factor-mediated coagulation.

Journal of thrombosis and haemostasis : JTH·2018
Same journal

Barriers and enablers to non-remunerated plasma donation: A meta-synthesis of the qualitative literature using the theoretical domains framework.

Vox sanguinis·2026
Same journal

Haemolytic disease of the foetus and newborn due to anti-M: A systematic review.

Vox sanguinis·2026
Same journal

In vitro evaluation of apheresis platelet and plasma products collected and stored in non-DEHP disposable sets.

Vox sanguinis·2026
Same journal

Survey of national and regional rare donor programmes regarding Immunoglobulin A deficiency.

Vox sanguinis·2026
Same journal

Fibrinogen recovery in cryoprecipitate prepared from thawed plasma stored for 5 days post-thaw.

Vox sanguinis·2026
Same journal

Abstracts of the 39th International Congress of the ISBT, Kuala Lumpur, Malaysia, 20-24 June 2026.

Vox sanguinis·2026
See all related articles

Foreign surfaces activate complement, causing inflammation and organ rejection. Complement inhibitors and heparin coatings improve material biocompatibility, reducing adverse reactions.

Area of Science:

  • Biomaterials science
  • Immunology
  • Medical device engineering

Background:

  • Blood contact with foreign surfaces triggers defense system activation, notably complement.
  • Complement activation contributes to inflammatory reactions in cardiopulmonary bypass and hyperacute xenograft rejection.

Purpose of the Study:

  • To investigate the role of complement in inflammatory responses to artificial surfaces and foreign endothelium.
  • To evaluate the efficacy of complement inhibitors and surface modifications in improving biocompatibility.

Main Methods:

  • Utilized complement-specific inhibitors to study complement activation pathways.
  • Assessed the impact of heparin coating on artificial surfaces for coagulation and complement compatibility.
  • Examined the terminal SC5b-9 complex (TCC) as a bioincompatibility indicator.

Related Experiment Videos

Main Results:

  • Complement activation is a key factor in the inflammatory response to artificial surfaces and xenografts.
  • Terminal Complement Complex (TCC) serves as a sensitive marker for bioincompatibility.
  • Heparin coating enhances the coagulation and complement compatibility of artificial surfaces.

Conclusions:

  • Complement plays a critical role in adverse reactions to artificial materials and foreign tissues.
  • Specific complement inhibitors and surface modifications like heparin coating significantly improve biomaterial biocompatibility.